About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.
minkabu the infonoid
(C) 2024 MINKABU THE INFONOID, Inc.
kabutan

Chordia Therapeutics Inc.(190A) Summary

190A
TSE Growth
Chordia Therapeutics Inc.
248
JPY
+12
(+5.08%)
Apr 10, 3:30 pm JST
1.68
USD
Apr 10, 2:30 am EDT
Result
PTS
outside of trading hours
Summary Chart Historical News Financial Result
PER
PBR
4.80
Yield
ー%
Margin Trading Ratio
531.43
Stock Price
Apr 10, 2025
Opening Apr 10, 9:03 am
249 JPY 1.69 USD
Previous Close Apr 9
236 JPY 1.62 USD
High Apr 10, 9:03 am
250 JPY 1.69 USD
Low Apr 10, 9:21 am
240 JPY 1.63 USD
Volume
786,800
Trading Value
0.19B JPY 1.32M USD
VWAP
245.39 JPY 1.67 USD
Minimum Trading Value
24,800 JPY 168 USD
Market Cap
0.02T JPY 0.12B USD
Number of Trades
594
Liquidity & Number of Trades
As of Apr 10, 2025
Liquidity
High
1-Year Average
4,508
1-Year High Jul 26, 2024
40,334
Margin Trading
Date Short Interest Long Margin Positions Ratio
Apr 4, 2025 0 5,274,800
Mar 28, 2025 0 5,746,700
Mar 21, 2025 0 5,773,300
Mar 14, 2025 0 6,052,800
Mar 7, 2025 0 6,400,400
Company Profile
Chordia Therapeutics Inc. engages in the development of cancer therapeutics targeting RNA regulation stress.
Sector
Pharmaceuticals
Chordia Therapeutics Inc. is a drug discovery venture company specializing in the research and development of novel anti-cancer drugs targeting RNA regulation stress. The company has multiple pipelines including CLK inhibitors, MALT1 inhibitors, and CDK12 inhibitors, aiming to create groundbreaking first-in-class pharmaceuticals. Clinical trials are currently underway for acute myeloid leukemia, ovarian cancer, and other indications. Chordia Therapeutics actively promotes collaborative research and licensing partnerships with universities, public institutions, and pharmaceutical companies to achieve efficient drug discovery operations. The company is also expanding its partnering strategy, as exemplified by the licensing agreement for MALT1 inhibitors with Ono Pharmaceutical Co., Ltd.